Full-Time

Staff / Senior Scientist

Assay Development, Chemistry

Updated on 9/4/2026

Glyphic Biotechnologies

Glyphic Biotechnologies

11-50 employees

Next-generation protein sequencing platform provider

Compensation Overview

$123k - $187.6k/yr

+ Employee stock options

Berkeley, CA, USA

In Person

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Chemical Biology
Biochemistry

Get referred to Glyphic Biotechnologies

See people who can refer or advise you

Requirements
  • An advanced degree, specifically a master's or PhD, in organic chemistry, chemical biology, biochemistry, or a related field.
  • Industry experience designing multi-step chemical workflows in complex biological systems, including sequencing or determining the order of chemical manipulations across assay conditions.
  • At least 6 years of experience with a master's degree or 4 years with a PhD for the Senior Scientist level.
  • At least 8 years of experience with a master's degree or 6 years with a PhD for the Staff Scientist level.
  • Demonstrated experience developing site-selective bioconjugation chemistry for native peptides, including N-terminal, C-terminal, and side-chain modification strategies, using click chemistry such as CuAAC, SPAAC, and IEDDA, NHS-ester coupling, and related bioorthogonal approaches in multi-component peptide systems.
  • Experience developing multi-step workflows using peptides, oligonucleotides, and bioconjugation techniques in solution and on surfaces.
  • Proficiency with analytical characterization of complex conjugates and assay intermediates using HPLC, including RP and IEX, LC-MS/MS, and UV-Vis, with the ability to develop and validate analytical methods for novel chemical entities.
  • A history of building and adapting new chemical approaches rather than executing established protocols.
  • Ability to function as both an independent contributor and a collaborative partner in a cross-functional team environment.
  • Ability to solve problems and maintain attention to detail.
  • Strong written and verbal communication skills sufficient to work with colleagues from diverse scientific and technical backgrounds.
  • Ability to thrive in a fast-paced environment with evolving priorities.
Responsibilities
  • Optimize bioconjugation methods for peptide loading into the expansion assay and establish robust, high-efficiency loading protocols across diverse peptide populations and physicochemical characteristics.
  • Identify, characterize, and optimize peptide labeling during the ProSE sequencing assay using mechanistic understanding of Edman chemistry and amino acid side-chain reactivity and stability.
  • Develop reagents and methods to maximize the stability of peptides, DNA, and peptide-DNA chimeras throughout the ProSE sequencing assay.
  • Partner with the Chemistry team to develop amino acid side-chain protection chemistries.
  • Evaluate compatibility of new chemistries with existing assay components, reagents, and multi-cycle sequencing conditions.
  • Evaluate emerging chemistries from the literature and internal pipeline, and synthesize and test candidate reagents.
  • Design and determine the order of chemical manipulations within the assay workflow, including when steps occur on-bead versus off-bead and how side-chain protection and deprotection strategies are sequenced relative to assay cycles.
  • Optimize selective cleavage chemistry workflows for use within the sequencing assay.
  • Optimize chemical workflows for efficiency, selectivity, and compatibility with assay conditions.
  • Develop stabilization strategies for sensitive assay intermediates and conjugates.
  • Use HPLC, including RP and IEX, LC-MS/MS, UV-Vis, and CE to characterize conjugation efficiency, adduct identity, purity, and stability of assay intermediates and conjugates.
  • Characterize and troubleshoot the impact of chemical steps in multi-cycle workflows.
Desired Qualifications
  • Familiarity with nanopore or single-molecule sequencing chemistry and its demands on assay reagent purity, stability, and uniformity.
  • Experience with solid-phase peptide synthesis, including on-resin modification, selective side-chain deprotection, and non-standard protecting-group strategies.
  • Familiarity with statistical and design-of-experiments-based experimental design for chemistry optimization.
  • Prior experience in an early-stage biotechnology or tools/diagnostics company.
Glyphic Biotechnologies

Glyphic Biotechnologies

View

Glyphic Biotechnologies is advancing proteomics by building a next-generation protein sequencing platform. The core product is designed to reveal detailed information about proteins, helping researchers and medical institutions gain new insights into biology and disease. The platform supports sequencing services for researchers and may be licensed to other organizations, generating revenue from service fees and licensing agreements. Unlike many competitors that focus on smaller-scale tools, Glyphic emphasizes a first-of-its-kind sequencing capability for proteins, along with diverse deployment options (serving research labs directly and via licensing). The company's goal is to enable deeper understanding of bodily functions through protein data and to bring its sequencing technology to broader use in the life sciences through services and licensing deals.

Company Size

11-50

Company Stage

Early VC

Total Funding

$43M

Headquarters

New York City, New York

Founded

2021

Get referred to Glyphic Biotechnologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Greenhouse posted six Berkeley openings on September 4, 2026, signaling active buildout.
  • RTT Health lists Glyphic as partner, showing early external validation in 2026.
  • Company site updated September 2, 2026; operations continue after the reported $38 million Series A.

What critics are saying

  • No commercial product exists; a 2027 platform slip destroys investor patience.
  • Thermo Fisher and Bruker dominate proteomics; Glyphic must beat entrenched workflows.
  • If single-molecule chemistry fails, Glyphic becomes a perpetual R&D story, not a company.

What makes Glyphic Biotechnologies unique

  • Glyphic targets single-molecule protein sequencing, not incremental mass spectrometry improvements.
  • MIT spinout roots and Ed Boyden lineage give credible scientific pedigree.
  • Its Berkeley team still hires assay, chemistry, and proteomics talent in September 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Paid Maternity and Paternity Leave

Home Office Stipend

Wellness Program

Company Equity

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

0%
Labs of Latvia
Dec 3rd, 2024
Latvian LongeVC invests in US startup Glyphic Biotechnologies

Founded in New York in 2021 by Daniel Estandian and Joshua Yang, Glyphic Biotechnologies is developing a protein sequencing platform that uses single-molecule technology to analyze the sequence of each protein in a complex protein mixture.

BioPharmaTrend
Nov 25th, 2024
LongeVC Invests in Glyphic Biotechnologies

LongeVC has invested in Glyphic Biotechnologies, which is developing single-molecule protein sequencing technology. This innovation surpasses mass spectrometry by enabling precise sequencing of individual proteins in complex mixtures, enhancing protein analysis and broadening applications in drug discovery and diagnostics. The proteomics market, valued at over $30 billion, is set for growth with such advancements. This aligns with LongeVC's mission to support transformative healthcare technologies.

U.S. Securities and Exchange Commission
Feb 21st, 2024
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Johnson & Johnson Innovation
Apr 5th, 2023
Awardees of the BLUE KNIGHT™ Resident QuickFire Challenge Strive Toward Inflection Points | Johnson & Johnson Innovation

By: Rachel Rath, Director, BARDA Alliance, Johnson & Johnson Innovation – JLABS & Ashim Subedee, Director, DRIVe Catalyst Office, BARDA

Bakar Labs
Jan 31st, 2023
Glyphic Biotechnologies Wins $409K SBIR Grant From NIH - Bakar Labs

Congratulations to Glyphic Biotechnologies! NIH recently reported the company had been awarded a $409 SBIR grant for their project "Single-molecule protein sequencing by iterative isolation and identification of N-terminal amino acids." The company is developing and commercializing technology to sequence proteins — instead of DNA. They're hiring!